NEUP
Neuphoria Therapeutics Inc.3.9000
+0.0700+1.83%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
20.97MP/E (TTM)
-Basic EPS (TTM)
-4.02Dividend Yield
0%Recent Filings
8-K
AFFIRM-1 trial misses endpoints
Neuphoria Therapeutics announced on October 20, 2025, that its AFFIRM-1 Phase 3 trial of BNC210 for acute social anxiety disorder missed the primary endpoint and secondary measures, prompting discontinuation of the SAD program. The company will evaluate BNC210 for PTSD based on prior chronic dosing data and launch a full strategic review of operations by year-end, while its Merck partnership advances MK-1167 in Alzheimer's Phase 2, offering up to $450 million in milestones plus royalties. Cash stood at $14.2 million as of June 30, 2025, funding operations through Q2 2027. BNC210's safety profile remains favorable.
10-K
FY2025 results
Neuphoria Therapeutics posted FY2025 results marked by a $15 million milestone from Merck for advancing its α7 PAM program into Phase 2 Alzheimer's trials, bolstering cash amid pipeline progress. The year featured initiation of Phase 3 AFFIRM-1 for BNC210 in social anxiety disorder, with topline data eyed for Q4 2025, building on positive PTSD Phase 2b ATTUNE outcomes showing significant symptom reductions. Q4 momentum centered on Merck's trial start and a A$1 million Carina milestone for oncology licensing, while PTSD Phase 2b/3 SYMPHONY planning advanced. Liquidity strengthened via these non-dilutive inflows, funding near-term trials without new capex details. No annual guidance disclosed. Yet regulatory delays in CNS approvals loom large.
8-K
Nasdaq grants compliance extension
Neuphoria Therapeutics dodged a Nasdaq delisting bullet on September 10, 2025, when the exchange accepted its plan to fix a missed annual shareholder meeting for fiscal year-end June 30, 2024. The company now has until December 29, 2025, to hold the meeting after filing its overdue 10-K by September 29. Nasdaq compliance hangs in the balance. Yet risks persist if timelines slip.
8-K
Nasdaq compliance notice issued
Neuphoria Therapeutics received a Nasdaq deficiency notice on July 18, 2025, for failing to hold its annual stockholder meeting within 12 months of its June 30, 2024 fiscal year-end, violating Listing Rule 5620(a). The company plans to submit a compliance plan by September 1, 2025, targeting its annual meeting in November 2025 to regain compliance by December 29. Nasdaq listing remains unaffected for now. Compliance hinges on Nasdaq's approval.
10-Q
Q3 FY2025 results
Neuphoria Therapeutics swung to a $11.3 million net income in Q3 FY2025 ended March 31, 2025, fueled by a $15 million milestone from Merck's Phase 2 Alzheimer's trial start, driving revenue to $15 million from zero a year ago—while operating income hit $12.0 million versus a $2.4 million loss (derived). YTD through nine months, revenue reached $15.7 million including a $0.7 million Carina Biotech payment, yielding $8.5 million net income against a $12.8 million loss last year, with diluted EPS at $3.75 (anti-dilution from out-of-money warrants flagged). Cash climbed to $17.0 million, bolstered by $3.7 million operating cash flow, no debt, and $0.8 million from ATM equity sales; free cash flow not disclosed in the 10-Q. The redomiciliation to Delaware closed December 2024 seamlessly. Yet regulatory hurdles in advancing BNC210 for anxiety disorders loom large.
ACAD
ACADIA Pharmaceuticals Inc.
26.80-0.46
BTAI
BioXcel Therapeutics, Inc.
1.88+0.01
EPRX
Eupraxia Pharmaceuticals Inc.
6.25+0.09
JANX
Janux Therapeutics, Inc.
14.65-0.47
NCNA
NuCana plc
3.56-0.06
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NXTC
NextCure, Inc.
11.12-0.35
RAPP
Rapport Therapeutics, Inc.
30.76+1.16
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60